Featured Research

from universities, journals, and other organizations

Aggressive, early intervention with disease-modifying drugs improves outcomes for psoriatic arthritis patients

Date:
October 27, 2013
Source:
American College of Rheumatology (ACR)new
Summary:
People with psoriatic arthritis who receive early, aggressive pharmacologic intervention following a treat-to-target approach show better outcomes than those who receive standard care, according to new research.

People with psoriatic arthritis who receive early, aggressive pharmacologic intervention following a treat-to-target approach show better outcomes than those who receive standard care, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

Related Articles


Psoriatic arthritis is a type of arthritic inflammation that occurs in about 15 percent of patients who have a skin rash called psoriasis. This particular arthritis can affect any joint in the body, and symptoms vary from person to person.

Research has shown that persistent inflammation from psoriatic arthritis can lead to joint damage, and researchers at the University of Leeds in the United Kingdom investigated the differences in outcome measurements among two groups of psoriatic arthritis patients. The first group was treated according to a tight control approach, following specific guidelines on use of disease-modifying antirheumatic drugs (called DMARDs) to reach set targets in disease-related measurements. The second group was treated with a standard care approach.

The researchers' overarching goal was "to replicate similar findings in other inflammatory arthropathies, notably rheumatoid arthritis, where a treat-to-target approach is known to favorably influence long-term outcomes for these patients," says Philip Helliwell, MD; senior lecturer in rheumatology; Leeds Institute of Rheumatic and Musculoskeletal Medicine; and an investigator in the study.

Using data from eight medical treatment centers in the UK from 2008 to 2012, the researchers identified 206 people with psoriatic arthritis and tracked their progress for 48 weeks according to their treatment protocol. The patients in the tight control group were treated with escalating therapy if they did not meet minimal disease activity criteria at set time intervals. These patients were started on the DMARD methotrexate with rapid escalation to a dose of 25mg after six weeks if they tolerated the drug. After 12 weeks, if their disease was not controlled according to the criteria, these patients received a more powerful combination of DMARDs.

After another 12 weeks, if these patients had three or more tender or swollen joints, they were given anti-tumor necrosis factor (Anti-TNF) therapy. If they had less than three tender or swollen joints, but still did not meet the minimal disease activity criteria, they were given methotrexate and an alternative DMARD in combination. The standard treatment group was treated with DMARDS, but with no set time limits for drug therapy escalation or measurements to reach.

The researchers measured the outcomes of the two groups of patients according to the ACR20, ACR50 and ACR70 criteria for disease activity (essentially representing 20, 50, and 70 percent improvement). In the tight control group, 55 percent achieved ACR20, 44 percent achieved ACR50 and 33 percent achieved ACR70. In the standard care group, 37 percent achieved ACR20, 21 percent achieved ACR50 and 15 percent achieved ACR70.

These significant differences show that an aggressive, targeted approach to treating psoriatic arthritis greatly improves disease-activity outcomes for patients with psoriatic arthritis, the researchers concluded. "For the first time, it has been shown that aggressive treatment of inflammation in psoriatic arthritis gives better outcomes," explains Dr. Helliwell. "Further, the target used in the study -- minimal disease activity -- assesses a wide spectrum of disease features, including skin and enthesitis, and not just the articular aspects of this complex disease. Patients with this disorder have to endure several different disease manifestations. This study has shown that appropriate targeted therapy can be effective across all these aspects, an important finding for the person with this disorder."


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR)new. Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR)new. "Aggressive, early intervention with disease-modifying drugs improves outcomes for psoriatic arthritis patients." ScienceDaily. ScienceDaily, 27 October 2013. <www.sciencedaily.com/releases/2013/10/131027122927.htm>.
American College of Rheumatology (ACR)new. (2013, October 27). Aggressive, early intervention with disease-modifying drugs improves outcomes for psoriatic arthritis patients. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2013/10/131027122927.htm
American College of Rheumatology (ACR)new. "Aggressive, early intervention with disease-modifying drugs improves outcomes for psoriatic arthritis patients." ScienceDaily. www.sciencedaily.com/releases/2013/10/131027122927.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins